Business
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
Jeuveau® Recognized as Single Most Successful New Aesthetic Product Launched Since 2019 NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS),
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\nJeuveau® Recognized as Single Most Successful New Aesthetic Product Launched Since 2019\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today celebrates the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics. Launched in May 2019, Jeuveau® has been the single most successful new aesthetic product launched in the U.S. since 2019.1\n\n“Evolus continues to exceed expectations and gain momentum in our third year as a commercial company,” said David Moatazedi, President and CEO of Evolus. “Our strong results are directly linked to our singular focus on Jeuveau®, building a brand for the millennial consumer, the fastest growing patient segment of neurotoxin users, and our differentiated co-branded marketing strategy with our customers. We are grateful to our customers for their confidence in Jeuveau® and continued partnership.”\n\nAn estimated 2 million treatments of Jeuveau® have been administered by more than 7,500 purchasing customers nationwide. The accelerated growth is largely due to the adoption of a first-in-class co-branded marketing strategy, along with its cash pay business model. The co-branded marketing model offers customers a wide range of advertising options, including digital ads, billboards, and most recently, streaming television advertisements, with a direct call to action to book appointments using a smartphone and QR code.\n\n“As we celebrate three years since the launch of Jeuveau®, Evolus is especially proud of our unique, co-branded marketing strategy,” said Crystal Muilenburg, Chief Marketing Officer. “We have worked collaboratively with our customer base to launch more than 4,300 individualized campaigns, putting Jeuveau® quite literally on the map across the country.”\n\nIn the near future, Evolus leadership anticipates reaching several monumental milestones, including:\n\n\nThe launch of its product in Europe under the brand name Nuceiva®, anticipated in Q3 2022;\n\n\nThe progress of its Phase II trial evaluating an “extra-strength,” extended duration dose of Jeuveau® (anticipated completion date of early 2023);\n\n\nAn expected regulatory approval in...